
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd has strengthened its position in the regenerative medicine and aesthetics sectors, which enhances its long-term growth potential. The company's partnership with AbbVie has resulted in $24 million of milestone payments, indicating strong commercial viability for its rhCollagen technology and reinforcing corporate confidence in its applications. Additionally, the recent patent securing CollPlant's intellectual property until 2039 consolidates its competitive edge in the aesthetics market and supports ongoing advancements toward human trials.
Bears say
CollPlant Biotechnologies Ltd faces a challenging financial landscape characterized by reliance on a limited number of revenue streams, primarily from collaborations and niche product sales in the regenerative medicine and aesthetics sectors. The company's dependence on advanced technologies for 3D bioprinting of tissues and organs may hinder its ability to scale effectively due to high entry barriers and increased competition within the biotechnology field. Furthermore, the fluctuating market demand for rhCollagen related products and the ongoing need for significant investment in research and development could impede consistent revenue growth and overall financial stability.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares